BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 16908524)

  • 1. Pro-urokinase-type plasminogen activator is a substrate for hepsin.
    Moran P; Li W; Fan B; Vij R; Eigenbrot C; Kirchhofer D
    J Biol Chem; 2006 Oct; 281(41):30439-46. PubMed ID: 16908524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
    Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
    Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.
    List K; Jensen ON; Bugge TH; Lund LR; Ploug M; Danø K; Behrendt N
    Biochemistry; 2000 Jan; 39(3):508-15. PubMed ID: 10642175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.
    Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D
    Eur J Biochem; 1988 Nov; 177(3):575-82. PubMed ID: 2973984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).
    Kobayashi H; Schmitt M; Goretzki L; Chucholowski N; Calvete J; Kramer M; Günzler WA; Jänicke F; Graeff H
    J Biol Chem; 1991 Mar; 266(8):5147-52. PubMed ID: 1900515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.
    Bekes EM; Deryugina EI; Kupriyanova TA; Zajac E; Botkjaer KA; Andreasen PA; Quigley JP
    Neoplasia; 2011 Sep; 13(9):806-21. PubMed ID: 21969814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase.
    Kilpatrick LM; Harris RL; Owen KA; Bass R; Ghorayeb C; Bar-Or A; Ellis V
    Blood; 2006 Oct; 108(8):2616-23. PubMed ID: 16794252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L.
    Goretzki L; Schmitt M; Mann K; Calvete J; Chucholowski N; Kramer M; Günzler WA; Jänicke F; Graeff H
    FEBS Lett; 1992 Feb; 297(1-2):112-8. PubMed ID: 1551416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
    Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
    Vines DJ; Lee SW; Dichek DA; Ellis V
    J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
    Petersen LC
    Eur J Biochem; 1997 Apr; 245(2):316-23. PubMed ID: 9151959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase.
    Suzuki M; Kobayashi H; Kanayama N; Saga Y; Suzuki M; Lin CY; Dickson RB; Terao T
    J Biol Chem; 2004 Apr; 279(15):14899-908. PubMed ID: 14747469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
    Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
    Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
    Meissauer A; Kramer MD; Schirrmacher V; Brunner G
    Exp Cell Res; 1992 Apr; 199(2):179-90. PubMed ID: 1531956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase-type plasminogen activator is a preferred substrate of the human epithelium serine protease tryptase epsilon/PRSS22.
    Yasuda S; Morokawa N; Wong GW; Rossi A; Madhusudhan MS; Sali A; Askew YS; Adachi R; Silverman GA; Krilis SA; Stevens RL
    Blood; 2005 May; 105(10):3893-901. PubMed ID: 15701722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R; Biliran H; Sager R; Sheng S
    Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles and regulation of membrane-associated serine proteases.
    Qiu D; Owen K; Gray K; Bass R; Ellis V
    Biochem Soc Trans; 2007 Jun; 35(Pt 3):583-7. PubMed ID: 17511657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
    Schmitt M; Goretzki L; Jänicke F; Calvete J; Eulitz M; Kobayashi H; Chucholowski N; Graeff H
    Biomed Biochim Acta; 1991; 50(4-6):731-41. PubMed ID: 1801751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin.
    Schmitt M; Kanayama N; Jänicke F; Hafter R; Graeff H
    Adv Exp Med Biol; 1991; 297():111-28. PubMed ID: 1837419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.